Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03294863
Other study ID # 101077
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 15, 2017
Est. completion date March 2028

Study information

Verified date June 2023
Source University of California, Davis
Contact Daniel B Eisen, MD
Phone 916-551-2636
Email dbeisen@ucdavis.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the use of the embrace device after repair of linear cutaneous surgery wounds improves scar cosmesis.


Description:

The purpose of this study is to determine whether the use of the embrace device after repair of linear cutaneous surgery wounds improves scar cosmesis. We will use a split wound model, half of the wound is treated with the embrace device and the other half is not treated. Three-months post-surgery, the scar will be measured via the physician observer scar assessment scale, a validated scar instrument. The scar width and adverse events will also be recorded. Following the surgical repair of cutaneous wounds, scar formation is inevitable and results in varying degrees of aesthetic and/or functional impairment. Numerous treatment modalities have been employed to treat scars. Carbon dioxide and pulse dye lasers, as well as dermabrasion can reduce erythema and irregular topology of the scar surface1,2. Silicone-based products have also been used to treat post-surgical scars, including gels, sheets, and tape3-5. Intralesional steroids are often injected into to induce flattening of a scar6. More recent research has highlighted the impact of mechanical forces and tension on scar formation. In one report, incisions in both pigs and humans were treated with a tension-shielding device and showed a reduction in scarring7. More recently two clinical trials have been published in the plastic surgery literature showing that the use of the embrace device, a silicone-based dressing designed to minimize wound tension, is effective in improving the aesthetic outcome following scar revision surgery8,9. While these initial studies of the embrace device have promising findings, there are significant drawbacks to both studies including small study population, inclusion of patients seeking scar revision (a select group likely predisposed to poor scar cosmesis and not representative of first-time surgical patients), investigator conflict of interest, and the use of a digital software-based scar assessment tool using patients photos that were not standardized with respect to lighting or distance. Therefore, larger studies in first-time surgical patients with standardized photos for scar assessment are required to validate this potentially promising device for improved scar cosmesis.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date March 2028
Est. primary completion date March 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age or older - Able to give informed consent themselves - Patient scheduled for cutaneous surgical procedure along a flat surface suitable to application of the embrace with predicted primary closure. - Able to apply dressings themselves. - Willing to return for follow up visits. Exclusion Criteria: - Mentally handicapped - Unable to understand written and oral English - Incarceration - Under 18 years of age - Pregnant Women - Wounds with predicted closure length less than 3 cm - Patients with known adverse reactions to adhesives - Patients with history of collagen vascular disease

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Embrace Scar Therapy Device
16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
Other:
Standard of Care
Without the embrace Scar Therapy Device

Locations

Country Name City State
United States University of California, Davis, Department of Dermatology Sacramento California
United States University of California, Davis, Department of Dermatology Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Physician observer scar assessment score (POSAS) Comparison of scar cosmesis over area of wound that was treated with the device as compared to area that was not treated with the device. 3 months
Primary Width of the scar The width of the scar on both sides will also be measured and recorded 1 cm from midline on both sides of the scar 3 months